Putting a CAP on the recommendations for community acquired pneumonia, here’s the tweetorial promised below! 🔑 pearls on the 2019 updates! 📝 #ACCPAM19
https://twitter.com/theABofPharmaC/status/1188095500693770241
Top of the iceberg was a discussion of DUAL vs. MONOtherapy: is BL therapy alone ✅ for CAP? 🤔
Not so fast! 🏃
BL monotherapy has yet to take prime time, up to 40% of patients received atypical coverage in the CAP-START study. So for now, ✌️ is > ☝️
Not so fast! 🏃
BL monotherapy has yet to take prime time, up to 40% of patients received atypical coverage in the CAP-START study. So for now, ✌️ is > ☝️
Next up, HCAP is 💀 #nuffsaid
To roid or not to roid? 💪
In severe CAP, there is no benefit of corticosteroids in CAP with only ⤴️risk of ADRs such as hyperglycemia and infection.
🛑 So, say no to steroids!
In severe CAP, there is no benefit of corticosteroids in CAP with only ⤴️risk of ADRs such as hyperglycemia and infection.
🛑 So, say no to steroids!
Then there’s the new kid on the block.. delafloxacin FDA approved for CAP. Impressed this made it in! @emilylheil stressed, please avoid FQs at all costs possible!
⤴️ADRs &♥️cardiovascular events with FQs, so save for patients with only need for FQs such as true BL allergies!
⤴️ADRs &♥️cardiovascular events with FQs, so save for patients with only need for FQs such as true BL allergies!
Now those ASP can take a deep “breath” and relax in knowing , no more clinda for aspiration pneumonia! Great job @emilylheil 👏🏻 #ACCPAM19
• • •
Missing some Tweet in this thread? You can try to
force a refresh
